Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

NCT02601950 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT02601950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02601950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Lead sponsor
Epizyme, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 22, 2015
Completion date
February 26, 2024
Enrollment
267 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

any solid tumor with an ezh2 gof mutation, atypical teratoid rhabdoid tumors (atrt), epithelioid sarcoma, ini1-negative tumors, malignant rhabdoid tumor of ovary, malignant rhabdoid tumors (mrt), poorly differentiated chordoma (or other chordoma with sponsor approval), renal medullary carcinoma, rhabdoid tumors of the kidney (rtk), selected tumors with rhabdoid features, synovial sarcoma